Ray Therapeutics Appoints New Chief Financial Officer
Ray Therapeutics, a prominent player in the optogenetics field, has announced the appointment of Christopher Whitmore as its new Chief Financial Officer. This significant decision comes at a crucial time as the company seeks to innovate solutions that could help restore vision for patients affected by degenerative retinal diseases.
Christopher Whitmore’s Background and Expertise
Mr. Whitmore brings over 20 years of experience in strategic finance, accounting, and operations to this role. His extensive background includes various positions ranging from emerging biotech companies to well-established public firms. Most recently, he served as CFO at Immune-Onc, where he led key efforts in securing funding and promoting clinical trials.
Contributions to the Biotechnology Sector
At Immune-Onc, Christopher played a vital role in forming partnerships with major pharmaceutical companies, including Roche and Beigene. His leadership experience at notable organizations like Harpoon Therapeutics and Immune Design, both of which were acquired by Merck, further underscores his expertise in the biotech industry.
Comments from the CEO on the New Appointment
Paul Bresge, the CEO of Ray Therapeutics, expressed his excitement about Christopher joining the organization. He stated, "Chris brings extensive experience leading high-performing teams in both the private and public sectors. He has a proven track record of success in our industry, and we are thrilled to welcome him to the team as we enter an exciting new phase of development." Mr. Bresge highlighted the valuable contributions Whitmore is expected to bring to the company’s advancing clinical pipeline.
A Vision for the Future
After his appointment, Christopher Whitmore shared his enthusiasm for taking on this role, emphasizing the mission of the company to harness optogenetics for individuals experiencing vision loss. "I’m excited to join Ray Therapeutics at such a dynamic time and I couldn’t be prouder to support the company’s mission to demonstrate the power and restorative capabilities of optogenetics for those with significant unmet needs," he remarked.
Early Career of Mr. Whitmore
Christopher's career began at KPMG LLP, where he worked as a manager in the audit department. He holds a B.A. in Business Economics from the University of California, Santa Barbara, and has an active CPA license, showcasing his commitment to financial proficiency.
About Ray Therapeutics
Ray Therapeutics is leading the charge in developing cutting-edge optogenetic gene therapies that address blinding diseases. Their main candidate, RTx-015, targets retinitis pigmentosa, a condition that leads to the progressive degeneration of the retina and highlights the urgent need for effective treatment. The company's broader mission is to restore vision in patients with inherited retinal diseases, regardless of genetic variations. Based in Berkeley, Ray Therapeutics is dedicated to advancing its research and clinical initiatives.
Frequently Asked Questions
1. Who is the newly appointed CFO of Ray Therapeutics?
Christopher Whitmore is the newly appointed Chief Financial Officer of Ray Therapeutics.
2. What is the primary focus of Ray Therapeutics?
Ray Therapeutics focuses on developing optogenetics gene therapies aimed at restoring vision for patients with degenerative retinal diseases.
3. What prior experience does Christopher Whitmore bring?
Christopher Whitmore has over 20 years of experience in finance; he previously served as CFO at Immune-Onc and held roles at other biotechnology companies.
4. What is RTx-015?
RTx-015 is Ray Therapeutics' lead candidate focused on treating retinitis pigmentosa, a degenerative retinal disease.
5. Where is Ray Therapeutics headquartered?
Ray Therapeutics operates from Berkeley, California.
